




RealRate

PHARMACEUTICAL 2020

Zynerba Pharmaceuticals Inc.
Rank 145 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 344% points. The greatest weakness of Zynerba Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is -112%, being 190% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	87,056
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,058
Liabilities, Non-Current	110
Other Assets	346
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	363
Research and Development	20,384
Revenues	0
Selling, General and Administrative Expense	13,936

Output Variable	Value in 1000 USD
Assets	87,765
Liabilities	12,168
Expenses	34,320
Stockholders Equity	75,597
Net Income	-34,320
Comprehensive Net Income	-34,320
Economic Capital Ratio	-112%